Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
abstract:
Original paper

Real-world outcomes of immune checkpoint inhibitor monotherapy in later lines of recurrent/metastatic cervical cancer – evidence from a rescue access program in Poland

Renata Pacholczak-Madej
1
,
Maja Lisik-Habib
2, 3
,
Radosław Mądry
4
,
Monika Szarszewska
4
,
Zuzanna Borysiewicz
5
,
Katarzyna Gabalewicz
6
,
Ewa Iwańska
1
,
Wiktor Szatkowski
1
,
Mirosława Puskulluoglu
7
,
Jerzy Jakubowicz
1
,
Pawel Blecharz
1

  1. Department of Gynaecological Oncology, Maria Skłodowska-Curie National Institute of Oncology, Kraków, Poland
  2. Department of Proliferative Diseases, Copernicus Memorial Hospital, Łódź, Poland
  3. Comprehensive Cancer Centre and Traumatology, Łódź, Poland
  4. Department of Gynecological Oncology, Poznań University of Medical Sciences, Poznań, Poland
  5. Department of Oncology and Chemotherapy, Provincial Integrated Hospital, Elbląg, Poland
  6. Lower Silesian Oncology, Pulmonology and Haematology Centre, Wrocław, Poland
  7. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
Contemp Oncol (Pozn) 2025; 29 (4): 384–392
DOI: https://doi.org/10.5114/wo.2025.155581
Online publish date: 2025/10/28
View full text Get citation
 
PlumX metrics:
Introduction
Immune checkpoint inhibitors (ICIs) are a therapeutic option for recurrent/metastatic cervical cancer (r/mCC) following platinum-based chemotherapy. However, real-world data on their effectiveness and safety remain limited, particularly in Eastern Europe. This study evaluates the real-world outcomes of ICI monotherapy in pretreated patients with r/mCC.

Material and methods
This multicentre retrospective study included 39 patients with r/mCC who received ICI monotherapy (cemiplimab or pembrolizumab) after disease progression on platinum-based chemotherapy in 5 reference centres in Poland. The primary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate, and disease control rate (DCR). The secondary endpoint was treatment safety. Kaplan-Meier estimates were used for survival analysis, and Cox proportional hazards models assessed prognostic factors, with p < 0.05 considered statistically significant.

Results
After a median follow-up of 8.8 months, the median PFS was 5.7 months (95% confidence interval [CI] 4.9–6.4), and the median OS was 10.9 months (95% CI: 7.3–14.5). The objective response rate was 23% (n = 9), while the DCR was 64% (n = 25). Immune checkpoint inhibitors were generally well tolerated, with thyroid dysfunction, anaemia, and hepatic toxicity being the most common adverse events (AEs). The discontinuation of treatment due to AEs occurred in only 5% of the patients (n = 2). Immune-related adverse events (irAEs), particularly endocrine toxicities, were associated with significantly prolonged PFS (HR 0.2, 95% CI: 0.09–0.6, p = 0.001; HR 0.2, 95% CI: 0.06–0.6, p = 0.004, for the occurrence of irAEs and endocrine toxicities, respectively).

Conclusions
Immune checkpoint inhibitor monotherapy demonstrated modest efficacy in pretreated patients with r/mCC, with a manageable safety profile and irAEs of predictive significance for PFS.

keywords:

cervical cancer, immune checkpoint inhibitors, real-world data, cemiplimab, pembrolizumab
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.